FDA, Endo Freeze High-Stakes Drug Compounding Case
The U.S. Food and Drug Administration and Endo Pharmaceuticals Inc. on Wednesday froze high-stakes litigation over the agency's allegedly unlawful acquiescence to large-scale drug compounding, saying expected policy changes may address...To view the full article, register now.
Already a subscriber? Click here to view full article